LivaNova price target lowered to $56 from $60 at Mizuho

Mizuho lowered the firm’s price target on LivaNova to $56 from $60 and keeps a Neutral rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.